As Chinese and Indian Markets Expand, Young American Drug Outfits Should Hold Onto Ex-U.S. Rights, Says Genzyme Leader
This article was originally published in PharmAsia News
Executive Summary
BOSTON - Despite conventional wisdom and Wall Street's old-fashioned point of view, young American companies starting out should think long and hard before giving up ex-U.S. rights to their discoveries, the top executives of Massachusetts biotechs Genzyme and Biogen Idec advise
You may also be interested in...
Genzyme's Manufacturing Problems Lead To Enforcement Action By FDA
FDA tells Genzyme a consent decree to ensure GMP compliance is likely, but firm notes sanctions would be related only to Allston Landing facility.
Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn
Despite agreeing to support Biogen's nominee slate, Icahn says he still will push for biotech sale.
Varied Outcomes Predicted On Icahn's Bid For Four Seats On Genzyme's Board
Activist investor Carl Icahn seeking the kind of gains similar to those he realized at Biogen Idec.